注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Fulcrum Therapeutics Inc是一家临床阶段的生物制药公司。该公司致力于改善基因定义的罕见疾病患者的生活。该公司开发了一种产品引擎,用于识别可调节基因表达的药物靶点,以治疗基因错误表达的已知根源疾病。该公司还致力于开发治疗肌肉疾病、中枢神经系统疾病和血液疾病的根本原因的药物。该公司使用其专利产品引擎来识别和验证药物靶点,并开发候选产品,以应对某些基因错误表达引起的疾病。其候选产品包括losmapimod,它是一种用于治疗面肩肱型肌营养不良症(FSHD)的小分子,FTX-6058是一种用于结合胚胎外胚层发育(EED)的小分子。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Kathryn Haviland | 46 | 2018 | Independent Chair of the Board |
Leslie Leinwand | - | - | Member of Scientific Advisory Board |
James J. Collins | 57 | 2017 | Independent Director |
Baziel van Engelen | - | - | Member of FSHD Clinical Advisory Board |
Sonja L. Banks | 54 | 2021 | Independent Director |
H. Lee Sweeney | - | - | Member of Scientific Advisory Board |
Silvere van der Maarel | - | - | Member of FSHD Clinical Advisory Board |
Rabi Tawil | - | - | Member of FSHD Clinical Advisory Board |
Donald E. Ingber | - | 2021 | Member of Scientific Advisory Board |
Jeffrey Statland | - | - | Member of FSHD Clinical Advisory Board |
Patrick Trojer | 50 | 2022 | Member of Scientific Advisory Board |
Robert J. Gould | 68 | 2016 | Director |
James Arthur Geraghty | 68 | 2016 | Independent Director |
Alan Ezekowitz | 69 | 2016 | Independent Director |
Katina Dorton | 65 | 2020 | Independent Director |
Alexander C. Sapir | 57 | 2023 | CEO, President & Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核